David Kirske - Jun 30, 2022 Form 4 Insider Report for CTI BIOPHARMA CORP (CTIC)

Role
EVP, Chief Financial Officer
Signature
David Kirske
Stock symbol
CTIC
Transactions as of
Jun 30, 2022
Transactions value $
-$94,426
Form type
4
Date filed
9/20/2022, 04:59 PM
Previous filing
Jun 17, 2022
Next filing
Oct 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC common stock Award $20.1K +9.52K +128.65% $2.12 16.9K Jun 30, 2022 Direct F1
transaction CTIC common stock Options Exercise $21.4K +22.6K +133.58% $0.95 39.5K Sep 16, 2022 Direct
transaction CTIC common stock Sale -$136K -22.6K -57.19% $6.02 16.9K Sep 16, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -22.6K -4.61% $0.00 467K Sep 16, 2022 Common Stock 22.6K $0.95 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan.
F2 This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
F3 One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.